[Click eStock] "Nextbiomedical, Expecting Increase in Exports of Endoscopic Hemostatic Agents"

Sangsangin Securities analyzed on the 11th that it expects an increase in exports of the hemostatic agent for endoscopy (Nexpowder™) by Nextbiomedical.

Researcher Ha Taegi of Sangsangin Securities explained, "Nexpowder has been approved by the domestic Ministry of Food and Drug Safety, the U.S. Food and Drug Administration (FDA), European CE, Canada, Singapore, and others," adding, "In 2020, it signed an exclusive global distribution contract with Medtronic, the world's number one medical device company based in the U.S., excluding Korea, Japan, and Greater China."

He continued, "It is currently being sold in 29 countries including Europe and the U.S.," and added, "It will rapidly grow in the global hemostatic market."

Researcher Ha analyzed, "Last month, the hemostatic agent for colonoscopy (Nexpowder™) received product approval from the U.S. FDA," and said, "Sales in the U.S. will rapidly increase starting from the third quarter of next year." He also expressed expectations that "next year will be a year to establish the foundation for sales, and from 2026, it will enter a phase of full-scale growth."

He predicted, "Sales will exceed 23 billion KRW next year," and "If it is listed in the U.S. guidelines in 2026, sales will increase rapidly."

This content was produced with the assistance of AI translation services.